Progenity Announces Expansion of Board of Directors

Company Focused on Diagnostic and Therapeutic Precision Medicine
Solutions in Prenatal and Perinatal Healthcare, Oncology, and

, a privately held biotechnology company, today announced the
expansion of its board of directors with four new directors to support
the company as it executes its plans to develop and commercialize
precision medicine solutions across its genomic/epigenomic, proteomic,
and microbiomic platforms. Progenity is pleased to welcome Jeffrey D.
Alter, John T. Bigalke, Samuel R. Nussbaum, MD, and Lynne Powell to its
board of directors.

“Our pipeline of diagnostic and therapeutic applications under
development continues to grow with innovative solutions aimed at
transforming prenatal, perinatal, and gastrointestinal healthcare,” said
Harry Stylli, PhD, CEO, Chairman of the Board, and Founder of Progenity.
“These accomplished individuals, with their combined experience in
finance, risk management, managed care, business and clinical strategy,
and policy will be a valuable resource for Progenity in advancing future
products into clinical practice and driving its mission to make
healthcare more precise and personal.”

Progenity’s pipeline of precision medicine solutions under development
includes novel products for noninvasive prenatal screening for monogenic
diseases, and assays related to preeclampsia, preterm birth, oncology,
and others. Progenity also aims to transform gastrointestinal (GI) based
healthcare and improve clinical outcomes through development of ingestible
molecular diagnostics and therapeutic
products for GI disorders such
as inflammatory bowel disease (IBD).

Jeffrey D. Alter has extensive experience in health plan
management, business strategy, and mergers and acquisitions. Mr. Alter
is currently President of Arcturus One Consulting and was formerly CEO
of UnitedHealthcare’s Commercial Group. During Mr. Alter’s 14 years with
UnitedHealthcare, he led its largest business unit, generating $51
billion in revenue. He was instrumental in instituting strategic
initiatives that significantly improved organic growth, client
relationships and retention rates. He also developed strategies that
expanded the geographic footprint and diversification of the business
portfolio, acquired new businesses, and improved product margin
stability. Mr. Alter also successfully led UnitedHealthcare’s
implementation of the Affordable Care Act. Prior to this, he served as
Senior Vice President of Strategic Financial Planning for Oxford Health
Plans, served as Vice President of Finance, Underwriting and Operations
at Vytra Health Plans, and spent ten years in finance and operations
roles for Grumman Aerospace Corporation and Harris Corporation. Mr.
Alter serves on several boards, including the Long Island
Association, the Board of Governors of St. John’s University, and
CityMD. He received a BS in marketing and an MBA in finance from St.
John’s University.

John T. Bigalke is a seasoned financial expert and a board member
and advisor to healthcare and life science companies. He is a Board
Leadership Fellow with the National Association of Corporate Directors.
Mr. Bigalke founded and is currently CEO of Second Half Healthcare
Advisors, where he consults on business strategy for companies competing
in the rapidly changing health care environment. His previous roles were
U.S. National Industry Leader and Senior Partner, Global Health Care and
Life Sciences at Deloitte LLP, where he led the growth to become the
leading professional services firm serving the industry. Mr. Bigalke led
a wide range of engagements over 18 years at Deloitte and 40 years in
the industry, providing audit, litigation support, mergers and
acquisitions, regulatory advisory and strategic planning services. He
also served as the National Director of Public Policy, leading the
development of Deloitte’s public policy strategy. Mr. Bigalke serves as
chairman of the Advisory Board at VaxCare Corporation and is a member of
the Board of Directors at Advent (formerly Adventist) Health Systems. He
is a Senior Advisor to Concord Management Services LLC. He previously
served on the Board of Directors of Deloitte LLP and the Healthcare
Financial Management Association, among others. He received a BS in
Financial Management from Clemson University and is a licensed Certified
Public Accountant.

Samuel R. Nussbaum, MD, is a clinical leader, academic physician,
and policy advisor to top healthcare companies. Dr. Nussbaum has
expertise in technology assessment and health economics for health plans
and private and public sector policy organizations. He currently serves
as a strategic consultant for EBG Advisors and a senior advisor to
Sandbox Industries and the Ontario Teachers’ Pension Plan. Previously,
Dr. Nussbaum served as Executive Vice President, Clinical Health Policy,
and Chief Medical Officer at Anthem for 15 years, where he oversaw
clinical strategy as well as medical and pharmacy policy. He was
responsible for over $100 billion in annual healthcare expenditures
through business units that focused on care management, health
improvement, and network contracting. He was instrumental in developing
contracting approaches that encouraged value-based care in hospitals,
and he built partnerships with federal agencies and academic
institutions to advance comparative effectiveness and outcome research.
Prior to that, Dr. Nussbaum was Executive Vice President, Medical
Affairs and System Integration at BJC Healthcare where he was
instrumental in developing alternative businesses and strategic
acquisitions that enabled business and clinical portfolio expansion. He
also spent two decades in academia at Massachusetts General Hospital and
Harvard Medical School, where he led the clinical endocrine group
practice. Dr. Nussbaum is a Professor of Clinical Medicine at Washington
University School of Medicine and a senior fellow at the USC Schaeffer
Center for Health Policy and Economics. He currently serves on a number
of boards, including Motus GI, Coherus Biosciences, and PhyMed. He
received a BA from New York University and an MD from the Mount Sinai
School of Medicine.

Lynne Powell is a commercial leader in the biotechnology and
biopharmaceutical industry. Ms. Powell is currently Senior Vice
President and Chief Commercial Officer at BioCryst Pharmaceuticals and
is responsible for formulating global commercial strategy and building
the commercial organization to launch BioCryst’s portfolio. Most
recently, she served as Senior Vice President, North America, at CSL
Behring, where she was accountable for the financial performance and
general management of all commercial activities within the U.S. and
Canada. Throughout her 17-year career at CSL Behring, she assumed
increasing responsibilities within the R&D and commercial functions of
the organization. She has significant global experience gained as Vice
President, Global Commercial Development and Head of Business
Development & European Marketing. Ms. Powell has launched multiple
products globally and in the U.S. Prior to her time at CSL, she held
positions of increasing responsibility within Glaxo Wellcome’s
commercial strategy and clinical research organizations. She received an
MBA from Monash University in Australia.

These new appointees join Dr. Stylli, along with the other current
Progenity board members, Jeffrey Ferrell, Managing Partner of Athyrium
Capital Management, and Howard Slutsky, Senior Vice President of
Commercial Operations at Progenity.

About Progenity

Progenity, Inc., is a privately held biotechnology company with the
mission of transforming healthcare to be more precise and personal. The
company is translating innovation into precision medicine through
diagnostic and therapeutic development platforms based on
genomics/epigenomics, proteomics, and microbiomics. These platforms feed
an R&D pipeline of innovative products designed to improve patient
outcomes in prenatal and perinatal healthcare settings, oncology, and
gastroenterology. Progenity’s ultimate vision is to make precision
medicine a reality by both diagnosing disease at its source and treating
it with targeted therapies developed by the company. Progenity is
headquartered in San Diego, California. For more information on how
Progenity is helping clinicians and patients prepare for life, please


Media Contact
Nicole Goelz
CG Life

Investor Contact

error: Content is protected !!